about
Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer.Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.Therapeutic targeting of integrin αvβ6 in breast cancer.Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I.Mammographic screening: a key factor in the control of breast cancer.A case-control study of the impact of the East Anglian breast screening programme on breast cancer mortality.Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy.Nutritional Evaluation and Optimisation in Neonates: a randomized, double-blind controlled trial of amino acid regimen and intravenous lipid composition in preterm parenteral nutrition.Visually assessed breast density, breast cancer risk and the importance of the craniocaudal viewExploring culturally competent primary care diabetes services: a single-city surveyClinical and epidemiological issues in mammographic density.Architecture and functioning of child and adolescent mental health services: a 28-country survey in Europe.A Comparison of Outcomes Following Laparoscopic and Open Hysterectomy With or Without Lymphadenectomy for Presumed Early-Stage Endometrial Cancer: Results From the Medical Research Council ASTEC Trial.Determinants of percentage and area measures of mammographic density.Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategies.Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention.Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias.Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern?Breast density and breast cancer risk factors in a high-risk population.Azathioprine treatment photosensitizes human skin to ultraviolet A radiation.The Swedish Two-County Trial of mammographic screening: cluster randomisation and end point evaluation.The Gothenburg Breast Screening Trial.Surgical dexterity after a 'night out on the town'.Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK.Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival.Population-based family case-control proband study on familial aggregation of metabolic syndrome: finding from Taiwanese people involved in Keelung community-based integrated screening (KCIS no. 5).All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point.A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales.Prevention of breast cancer in the context of a national breast screening programmeVolumetric and Area-Based Breast Density Measurement in the Predicting Risk of Cancer at Screening (PROCAS) StudyTamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control StudyNo evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, pParathyroid hormone related protein and skeletal morbidity in breast cancerThe West Midlands epithelial ovarian cancer adjuvant therapy trialA randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancerTime-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County StudyMeasuring performance in clinical breast examination
P50
Q25257412-F6A7BECD-7782-4FF1-AEE7-9A16523C16BBQ33244589-4E008864-9954-4D93-AEF8-3F4E89F18C50Q33944146-5A68A496-C0C4-4944-B5C2-9ECAC840BA26Q34120685-491B0114-523C-4C32-B2E2-EF9FEBB70A29Q34577467-5A15579A-9D40-4C4C-BE26-E32E018E1B31Q35000324-A2210913-A373-4DD7-84F8-82860E19CD3BQ35071990-014CDCA6-4CCA-4304-804C-389EAF29B6F7Q36608836-465C6DF1-E7AF-4265-959F-4AB78EFA5CF3Q36711033-84E521FB-421A-4284-B483-261D6F4B5875Q36937620-B503C687-44FD-46FE-A6FD-88B23A33CF33Q36955108-0D4A5039-927C-4986-BCB4-3807D995D7FDQ37337215-D23960F9-328D-4F3A-83F1-0AEE09255BD0Q37964937-619CDB0D-FEE9-4F46-9F51-3BE00F97A3C0Q38735544-163A38BE-2204-4690-9D3A-0E6FFA32FA23Q41512536-EF693FEF-AE3B-4CC9-8B0E-59009C990084Q43243211-FEF51FB9-4E8F-46C1-9FB5-93798B1105BCQ43429411-A6AE8E52-1390-4096-B2FC-15A8638B3054Q43761708-B9CA796E-1EF5-4401-89DE-9431A39EDA9CQ43818565-5D3257BF-5B2B-4148-AC9B-BE04C06B1E4BQ43828624-26454650-EB97-4C62-9C4A-84971EFFA730Q44096816-AFA91BEC-8873-44D8-AECD-98F3FCFA5678Q44310137-AD9C68EB-5F51-405C-8CC2-8B6BF33CB06BQ45289318-13C0E530-F309-4D79-8E86-D37879E3C796Q47735623-D09FC228-B1A1-4F37-A4F3-C9A90A5149B9Q47930972-12C88F74-4BA1-4908-B0FD-7FEE6FD74B8CQ48504425-8A4F7F0E-4967-4CB1-B7B6-039A237B9399Q51304817-443DB359-6EB3-494F-982D-03C286C5B89FQ51877946-A8B00240-9F14-4387-A058-3CC044C0D13BQ51934521-1B0A3929-B6DE-465D-B55D-F19981388F3BQ52947238-C0076052-8203-4190-91B6-A340274B93B3Q52970273-B56A6EF8-D3B3-4DB4-AA34-589CD4B1623AQ57266562-3B9090D1-23C2-4B23-8A39-2A1B52EC211BQ57266587-2003F393-B7A8-4B76-B130-1BB0C3673199Q59288218-7D104D9C-F19C-41A3-8FB6-A921D964C9BAQ59822600-A868664A-DFA1-4583-BDDF-0AA03E19AAE7Q68132980-90C9B44B-415E-416C-9694-5E710E1FE801Q70540411-0558310F-0DB4-4F5A-9C83-831CB9C07912Q71834403-A17CB36F-8B73-4905-AC70-486846864970Q79821845-41E41C3F-453B-4D31-AF65-477441257306Q84524353-F4251B47-2368-4136-8FF4-487B7E52E970
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jane Warwick
@ast
Jane Warwick
@en
Jane Warwick
@es
Jane Warwick
@nl
Jane Warwick
@sl
type
label
Jane Warwick
@ast
Jane Warwick
@en
Jane Warwick
@es
Jane Warwick
@nl
Jane Warwick
@sl
prefLabel
Jane Warwick
@ast
Jane Warwick
@en
Jane Warwick
@es
Jane Warwick
@nl
Jane Warwick
@sl
P106
P1153
7006375297
P21
P31
P496
0000-0002-7320-6603